Vasopressin Antagonists in the Treatment of Water-Retaining Disorders

Seminars in Nephrology

Volumn 28, Issue 3, 2008, Pages 279-288

  Kumar, Sumit ^a   Berl, Tomas ^b  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

antagonists; hyponatremia; treatment; Vasopressin

Indexed keywords

AQUAPORIN 2; CONIVAPTAN; LIXIVAPTAN; MOZAVAPTAN; PLACEBO; SATAVAPTAN; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SODIUM EXCRETION; THIRST; WATER RETENTION; XEROSTOMIA;

BODY WATER; HEART FAILURE; HUMANS; HYPONATREMIA; VASOPRESSINS;

EID: 44349101224     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.03.008     Document Type: Article

References (38)

1. Adrogue H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 (2000) 1581-1589
2. Anderson R.J., Chung H.M., Kluge R., and Schrier R.W. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102 (1985) 164-168
3. Hoorn E.J., Lindemans J., and Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 21 (2006) 70-76
4. Hawkins R.C. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 337 (2003) 169-172
5. Ellison D.H., and Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356 (2007) 2064-2072
6. Knepper M.A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 272 (1997) F3-F12
7. Chen S., Jalandhara N., and Batlle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract 3 (2007) 82-95
8. Berl T., and Schrier R.W. Disorders of water balance. In: Schrier R.W. (Ed). Renal and Electrolyte Disorders. 6th ed (2003), Lippincott Williams & Wilkins, Philadelphia 1-63
9. Thurman J., Halterman R., and Berl T. Therapy of dysnatremic disorders. Therapy in nephrology and hypertension. 2nd ed (2003), WB Saunders, Philadelphia
10. Mohmand H.K., Issa D., Ahmad Z., Cappuccio J.D., Kouides R.W., and Sterns R.H. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2 (2007) 1110-1117
11. Macion-Dazard R., Callahan N., Xu Z., Wu N., Thibonnier M., and Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 316 (2006) 564-571
12. Serradeil-Le Gal C., Lacour C., Valette G., Garcia G., Foulon L., Galindo G., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98 (1996) 2729-2738
13. Saito T., Ishikawa S., Abe K., Kamoi K., Yamada K., Shimizu K., et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82 (1997) 1054-1057
14. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110 (2001) 582-584
15. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
16. Soupart A., Gross P., Legros J.J., Alfoldi S., Annane D., Heshmati H.M., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1 (2006) 1154-1160
17. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
18. Ghali J.K., Koren M.J., Taylor J.R., Brooks-Asplund E., Fan K., Long W.A., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91 (2006) 2145-2152
19. Zeltser D., Rosansky S., van Rensburg H., Verbalis J.G., and Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27 (2007) 447-457
20. Walter K.A. Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm 64 (2007) 1385-1395
21. Kumar S., and Berl T. Sodium. Lancet 352 (1998) 220-228
22. Schrier R.W. Decreased effective blood volume in edematous disorders: what does this mean?. J Am Soc Nephrol 18 (2007) 2028-2031
23. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 138 (2001) 18-21
24. Gerbes A.L., Gulberg V., Gines P., Decaux G., Gross P., Gandjini H., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
25. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
26. Gheorghiade M., Abraham W.T., Albert N.M., Gattis Stough W., Greenberg B.H., O'Connor C.M., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 28 (2007) 980-988
27. Yancy C.W. Climbing the mountain of acute decompensated heart failure: the EVEREST Trials. JAMA 297 (2007) 1374-1376
28. Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
29. Gheorghiade M., Gattis W.A., O'Connor C.M., Adams Jr. K.F., Elkayam U., Barbagelata A., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
30. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
31. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
32. Abraham W.T., Shamshirsaz A.A., McFann K., Oren R.M., and Schrier R.W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47 (2006) 1615-1621
33. Udelson J.E., Smith W.B., Hendrix G.H., Painchaud C.A., Ghazzi M., Thomas I., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
34. Udelson J.E., McGrew F.A., Flores E., Ibrahim H., Katz S., Koshkarian G., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
35. Verbalis J.G. Vaptans for the treatment of hyponatremia: how, who, when and why. Nephrol Self Assessment Programs 6 (2007) 199-209
36. Furst H., Hallows K.R., Post J., Chen S., Kotzker W., Goldfarb S., et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 319 (2000) 240-244
37. Kumar S., and Berl T. Diseases of water metabolism. In: Schrier R.W., and Berl T. (Eds). Atlas of diseases of the kidney (1999), Blackwell Science: Philadelphia 1-22
38. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O'Connor C.M., Gheorghiade M., et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18